Cantor Fitzgerald Estimates Gossamer Bio FY2025 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Gossamer Bio in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer forecasts that the company will post earnings of ($0.72) per share for the year. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. The company had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Price Performance

GOSS stock opened at $0.90 on Wednesday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio has a 52-week low of $0.50 and a 52-week high of $1.60. The stock’s 50 day moving average is $0.84 and its two-hundred day moving average is $0.91. The company has a market capitalization of $204.40 million, a PE ratio of -2.82 and a beta of 1.81.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors have recently made changes to their positions in the company. NEA Management Company LLC increased its holdings in shares of Gossamer Bio by 14.2% in the 2nd quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock valued at $16,300,000 after acquiring an additional 2,255,025 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Gossamer Bio by 170.8% in the 2nd quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock valued at $3,002,000 after acquiring an additional 2,103,766 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Gossamer Bio by 204.7% in the 2nd quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company’s stock valued at $1,844,000 after acquiring an additional 1,375,000 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Gossamer Bio by 30.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock valued at $1,862,000 after acquiring an additional 442,895 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Gossamer Bio by 24.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock valued at $380,000 after acquiring an additional 74,920 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.